Accuracy of FVIII:C assay by one-stage method can be improved using hemophilic plasma as diluent

被引:22
作者
Cinotti, S
Paladino, E
Morfini, M
机构
[1] Univ Careggi, Agcy Hemophilia, I-50134 Florence, Italy
[2] Univ Careggi, Reg Reference Ctr Inherited Bleeding Disorders, Azienda Osped, Florence, Italy
关键词
FVIII assay; one-stage clotting method; hemophilia A; FVIII concentrates;
D O I
10.1111/j.1538-7836.2006.01880.x
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: the basic prerequisite of Factor VIII clotting assay (FVIII:C) by One-Stage Method is that all other than FVIII clotting factors are present in constant concentration in each dilution of both standard reference and patient's plasma curves. On the contrary, the plasma content of each dilution is decreasing as the dilution factor increases.Objectives and methods: to keep exactly constant the plasma content in each mixture, we performed all dilutions of both standard reference and patient's plasma with FVIII deficient plasma and further with a fixed amount of buffer (method B). To show the discrepancies between this method and regular method A, using buffer to make dilutions, a comparative study was conducted on FVIII: C assay on samples at known FVIII concentration and in patients' plasma. Imidazole or Owren's buffers and five different aPTT reagents were employed, both in method A and B.Results: a discrepancy between FVIII: C assays obtained by method A and B was observed, mainly when Pathrontin SL and Imidazole buffer were used. The assays derived from method B always better fit with the expected, calculated, values of FVIII:C concentrations. Furthermore, FVIII: C was assayed in 60 patients: the outcome of method A was always higher than values of method B. The discrepancy between the two methods was higher at FVIII concentrations below 50 U/dL but null at 100 U/dL. The A slope was steeper than B slope and the difference was statistically significant starting from the 1/10 dilution. Accordingly, FVIII: C of patients' plasma obtained by method A was always higher that those obtained by method B, even 2 or 3 times for FVIII level < 10 U/dL or 1.4-1.6 times for FVIII levels between 10 and 25 U/dL.Conclusions: only method B is able to give FVIII: C assays in agreement with the expected values. The dilution of reference standards and samples with FVIII deficient plasma is crucial to accurately evaluate the post-infusion FVIII concentrations in pharmacokinetic studies or the trough level during prophylactic therapy and to investigate the discrepancy among different FVIII: C assays. In addition, the assessment of severity and classification of hemophilia should be reviewed.
引用
收藏
页码:828 / 833
页数:6
相关论文
共 22 条
[1]  
BARROWCLIFFE TW, 1978, THROMB HAEMOSTASIS, V40, P260
[2]  
BARROWCLIFFE TW, 1993, THROMB HAEMOSTASIS, V70, P876
[3]   Discrepancies in potency assessment of recombinant FVIII concentrates [J].
Barrowcliffe, TW ;
Raut, S ;
Hubbard, AR .
HAEMOPHILIA, 1998, 4 (04) :634-640
[4]   Standardization of FVIII & FIX assays [J].
Barrowcliffe, TW .
HAEMOPHILIA, 2003, 9 (04) :397-402
[5]   Coagulation and chromogenic assays of factor VIII activity: General aspects, standardization, and recommendations [J].
Barrowcliffe, TW ;
Raut, S ;
Sands, D ;
Hubbard, AR .
SEMINARS IN THROMBOSIS AND HEMOSTASIS, 2002, 28 (03) :247-255
[6]   Laboratory aspects of haemophilia therapy [J].
Barrowcliffe, TW ;
Mertens, K ;
Preston, FE ;
Ingerslev, J .
HAEMOPHILIA, 2002, 8 (03) :244-249
[7]  
DAWSON NJ, 1989, HAEMOSTASIS, V19, P131
[8]   AN EFFECT OF PREDILUTION ON VIII-C DETERMINATION BY THE ONE STAGE ASSAY [J].
FRANDSEN, H ;
STENDER, S ;
SCHEIBEL, E .
THROMBOSIS RESEARCH, 1987, 48 (02) :195-203
[9]  
HARDISTY RM, 1962, THROMB DIATH HAEMOST, V7, P215
[10]   ASSAY OF AHF CONCENTRATES AND STANDARDS - FAILURE TO ELIMINATE VARIABILITY WITH A MONOGRAPHED ASSAY [J].
HELDEBRANT, C ;
KLESZYNSKI, R ;
SHORT, M ;
ARONSON, D ;
BROWN, L ;
JACOBY, G ;
LEE, M ;
THOMAS, D ;
BARROWCLIFFE, T ;
HOWELL, I ;
JOHNSON, RC .
THROMBOSIS RESEARCH, 1983, 30 (04) :337-346